Dediabetes Logo
Preguntas
Respuestas publicadas conectadas con evidencia
Referencia clínica
Dossieres detallados de intervenciones y resultados
Investigacion reciente
Estudios mas recientes
Acerca de
Cómo funciona deDiabetes
Configuracion
Entrar / Unirse
Resumen de Investigación
Analyzed using Evidence Intelligence™

Liraglutide and sitagliptin show no effect on liver fat in diabetes.

Desarrollado con el marco Evidence Intelligence™ de Dediabetes

Última actualización 12 de septiembre de 2026

Key finding

Liraglutide reduced steatosis by 10%.

This study evaluated the effects of liraglutide and sitagliptin on hepatic steatosis and fibrosis in type 2 diabetes but found no significant reductions.

Quick read

Study at a glance

The essential study design details in one scan.

EvidenceScore™

Moderate

Study type

RCTs

Follow-up

Medium-Term (3–12 mo)

Risk of bias

Some Concerns

Guarda investigacion, organiza estudios y vuelve a encontrar evidencia importante rapidamente.

Plain-language summary

What this paper says

A plain-language read of the study’s main message and where it applies.

Study focus

This study evaluated the effects of liraglutide and sitagliptin on hepatic steatosis and fibrosis in type 2 diabetes but found no significant reductions.

Clinical relevance

Understanding the effects of diabetes medications on liver health is crucial, especially as liver disease is a common complication in diabetes. This study indicates that liraglutide and sitagliptin may not be effective options for reducing liver fat or fibrosis, highlighting the need for alternative treatments or strategies in managing liver health in diabetic patients.

Keep in mind

The study duration of 12 weeks may not be sufficient to observe changes in liver conditions. The sample size and participant characteristics may limit generalizability. No significant p-values were reported, indicating uncertainty in the findings.

Published in

Referencia de la Revista

Publication details and source links for this paper.

Mark MS, Lennart T, Marcel HAM, et al. Twelve-week liraglutide or sitagliptin treatment does not reduce hepatic steatosis or fibrosis in type 2 diabetes. Diabetologia. 2016;59(12):2588-2593. doi:10.1007/s00125-016-4100-7

View DOIView on PubMedView on PMC

Efectos Principales

No significant reduction in hepatic steatosis was observed at week 12 across all treatment groups.

Neither liraglutide nor sitagliptin affected hepatic fibrosis scores compared to placebo.

Effect sizes indicated a decrease in hepatic steatosis percentages, but these were not statistically significant.

Evidence network

How this study fits

Understand where this research contributes within the broader evidence network.

Evidence Context

This study contributes evidence to Liraglutide, Sitagliptin and Liver fibrosis.

This study contributes evidence to

Intervention

Liraglutide

Outcome

Liver fibrosis

Evidence topic

DPP-4 Inhibitors

Primary intervention

Liraglutide

Primary outcomes

  • Liver fibrosis

Evidence topics

DPP-4 InhibitorsGLP-1 Receptor AgonistsLiraglutide

Primary intervention

Liraglutide

Primary outcomes

Liver fibrosis

Evidence relationships

Intervention and outcome relationships this study adds to the evidence network.

2
Evidence pairs
2
Relationships
3
Evidence topics
contributes_evidence

Editorial context

Why this study matters

See why this paper is useful beyond its individual results.

Evidence network role

This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.

Limited contributionModerate confidenceNetwork score: 44

3

Related topics

2

Evidence pairs

150

Related studies

High relevance in at least one topic

Why it is useful

  • Contributes to 2 evidence relationships
  • Linked to 3 direct semantic evidence topics

Topic contributions

Evidence topic

Contributes evidence

Evidence topic

Contributes evidence

Evidence topic

Contributes evidence

Agrega evidencia relacionada a tu Evidence Tracker

Guarda estudios y paginas de evidencia, organiza tu Evidence Tracker y manten en un solo lugar la investigacion que te importa.

Evidencia principal

Tema de evidencia

DPP-4 Inhibitors

matched_intervention

Evidencia relacionada

Tema de evidencia

GLP-1 Receptor Agonists

Guardar evidencia

Core evidence

Study findings

The primary outcomes reported in this study.

Liver fibrosis

Liraglutide → Liver fibrosis

Liraglutide → Liver fibrosis

Evidence Intelligence™
EvidenceScore™
Emerging
Score 59 · Based on 1 study
ImpactScore™
50
Neutral
ConsistencyScore™
unclear
Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence Tracker

Liver fibrosis

Sitagliptin → Liver fibrosis

Sitagliptin → Liver fibrosis

Evidence Intelligence™
EvidenceScore™
Emerging
Score 59 · Based on 1 study
ImpactScore™
50
Neutral
ConsistencyScore™
unclear
Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence Tracker

Evidence Library

Build your evidence library

Save research, organize studies, and quickly find important evidence again.

evidence suggest

La Evidencia Sugiere

  • Liraglutide showed a decrease in hepatic steatosis by -10% but was not statistically significant.
  • Sitagliptin demonstrated a decrease in hepatic steatosis by -12.1%, also not statistically significant.
  • Both drugs did not change hepatic fibrosis scores compared to placebo.
who this applies

A quién se aplica

  • Adults diagnosed with type 2 diabetes.
  • Individuals experiencing hepatic steatosis or fibrosis.
keep in mind

Tener en Cuenta

  • The findings may not apply to populations outside of the study sample.
  • Longer-term effects of these medications on liver health were not assessed.
  • The lack of significant findings suggests further research is needed to explore effective treatments.
between the lines

Entre Líneas

  • The study duration of 12 weeks may not be sufficient to observe changes in liver conditions.
  • The sample size and participant characteristics may limit generalizability.
  • No significant p-values were reported, indicating uncertainty in the findings.

Evidence Library

Build your evidence library

Save research, organize studies, and quickly find important evidence again.

Connected Evidence

Explore related studies, evidence collections, and research questions.

Relationships organized using the Dediabetes Evidence Intelligence™ framework.

Desarrollado con el marco Evidence Intelligence™ de Dediabetes

This study contributes to evidence on GLP-1 Receptor Agonists and Liver fibrosis, DPP-4 Inhibitors and Liver fibrosis.

Relaciones de evidencia relacionadas

Explore in Evidence Explorer

This study contributes to the evidence on the following intervention-outcome relationships.

Questions answered by this study

Generated from the study's connected evidence using Evidence Intelligence™.

Does Liraglutide improve liver fibrosis?

Emerging Evidence

Current evidence does not show a clear benefit of Liraglutide for liver fibrosis.

ConsistencyScore™: Consistency cannot yet be determined from the available evidence.

Ranked evidence signals

  1. 1

    Liver fibrosis

    EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study

Why this answer: This answer is based on a single supporting study.

Limitations

  • Only one supporting study is available.
1 supporting study
View Full Evidence

Does Sitagliptin improve liver fibrosis?

Emerging Evidence

Current evidence does not show a clear benefit of Sitagliptin for liver fibrosis.

ConsistencyScore™: Consistency cannot yet be determined from the available evidence.

Ranked evidence signals

  1. 1

    Liver fibrosis

    EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study

Why this answer: This answer is based on a single supporting study.

Limitations

  • Only one supporting study is available.
1 supporting study
View Full Evidence
Learn how Evidence Intelligence™ works

Next steps

Continue your research

Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.

Evidence topics

Follow the topics this study contributes to.

DPP-4 Inhibitors Evidence HubGLP-1 Receptor Agonists Evidence HubLiraglutide Evidence Hub

Explore in Evidence Explorer

Open broader Evidence Explorer views for this relationship.

All studies on Liraglutide and Liver fibrosisAll studies on Sitagliptin and Liver fibrosis

Related research

Read related research summaries.

Liraglutide is well tolerated in diabetes patients undergoing hemodialysis.Liraglutide may reduce stroke recurrence in type 2 diabetes patientsGLP-1RA improves metabolic outcomes in MASLDSitagliptin improves kidney function in type 1 diabetesGLP-1 and DPP-4 Inhibitors Show No Effect on Gallbladder Volume

Sin anuncios. Sin rastreo.

Centrada en la evidencia, no en la publicidad.

Segura y privada

Tus datos siempre están protegidos.

Siempre al día

Se agregan nuevos estudios todos los días.